Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Propanc Biopharma, Inc. - Common Stock (NQ:PPCB)

1.140 -0.010 (-0.87%)
Streaming Delayed Price Updated: 12:38 PM EDT, Aug 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,622
Open 1.140
Bid (Size) 1.120 (500)
Ask (Size) 1.180 (300)
Prev. Close 1.150
Today's Range 1.080 - 1.140
52wk Range 0.9500 - 52.50
Shares Outstanding 15,859,280
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP
Avance Clinical to Lead Preparatory Activities for Multi-Center Investigation Across Australia 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers
Contrasting Science with Revolution Medicines and Erasca 
From Propanc Biopharma, Inc.
Via GlobeNewswire

Performance

YTD
-92.0%
-92.0%
1 Month
-13.6%
-13.6%
3 Month
-34.5%
-34.5%
6 Month
-76.1%
-76.1%
1 Year
-97.5%
-97.5%

More News

Read More
News headline image
Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd
From Propanc Biopharma, Inc.
Via GlobeNewswire
Thursday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Propanc Biopharma Initiates $5.0 Million Share Repurchase Program
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study
From Propanc Biopharma, Inc.
Via GlobeNewswire
These stocks that are showing activity before the opening bell on Friday. ↗
Via Chartmill
Top movers analysis one hour before the close of the markets on 2026-06-11: top gainers and losers in today's session. ↗
Via Chartmill
These stocks are the most active in today's session ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain
From Propanc Biopharma, Inc.
Via GlobeNewswire
Which stocks are moving before the opening bell on Tuesday? ↗
Via Chartmill
News headline image
Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB
From Rosen Law Firm
Via Business Wire
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy
From Propanc Biopharma, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Propanc Biopharma, Inc. - Common Stock publicly traded?
Yes, Propanc Biopharma, Inc. - Common Stock is publicly traded.
What exchange does Propanc Biopharma, Inc. - Common Stock trade on?
Propanc Biopharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Propanc Biopharma, Inc. - Common Stock?
The ticker symbol for Propanc Biopharma, Inc. - Common Stock is PPCB on the Nasdaq Stock Market
What is the current price of Propanc Biopharma, Inc. - Common Stock?
The current price of Propanc Biopharma, Inc. - Common Stock is 1.140
When was Propanc Biopharma, Inc. - Common Stock last traded?
The last trade of Propanc Biopharma, Inc. - Common Stock was at 08/25/26 12:38 PM ET
What is the market capitalization of Propanc Biopharma, Inc. - Common Stock?
The market capitalization of Propanc Biopharma, Inc. - Common Stock is 18.08M
How many shares of Propanc Biopharma, Inc. - Common Stock are outstanding?
Propanc Biopharma, Inc. - Common Stock has 18M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.